Cardiovascular Radiology

Cardiac MRI measures aid in predicting future MACE after heart attack
By Liz Carey
Left atrial minimum volume index can help predict future major adverse cardiovascular events (MACE) after acute myocardial infarction.
September 16, 2025
2025 09 16 Ami Mace Study Radiology Thumbnail
Tempus AI secures 510(k) for Pixel
By AuntMinnie.com staff writers
The update reflects new software functionality designed for a comprehensive view of heart tissue.
September 12, 2025
Cardiac Heart Eeg Social (1)
Low-dose CT ties emphysema to mortality in previous smokers
By Amerigo Allegretto
Study findings highlight the clinical relevance of CT-diagnosed emphysema.
September 9, 2025
Representative axial images of mild, moderate, and severe emphysema at baseline low-dose CT (LDCT). Participants were categorized as having no emphysema or mild, moderate, or severe emphysema. When present, emphysema was mild if no distinct regions of reduced attenuation were visible on the CT scan, but vascular splaying indicates parenchymal expansion, or if only occasional discrete low-attenuation regions were observed. Moderate emphysema was defined by the presence of identifiable low-attenuation regions affecting less than half of the lung parenchyma, whereas severe emphysema was defined by the presence of identifiable low-attenuation regions that involved more than half of the lung parenchyma. A scoring system from 0 to 3 was applied, corresponding to none, mild, moderate, and severe emphysema, respectively. Yellow circle indicates the extent of emphysema. (A) A 67-year-old man with mild emphysema at baseline LDCT in 2002. Baseline LDCT scan shows vascular splaying, suggesting parenchymal expansion due to emphysema and occasional discrete low-attenuation regions. The participant ultimately died of cardiovascular disease 15.4 years (184.2 months) later. (B) A 69-year-old man with moderate emphysema at baseline LDCT in 2007. The participant died of cardiovascular disease 1.8 years (21.9 months) later. Identifiable low-attenuation regions affected less than half of the lung parenchyma. (C) An 85-year-old woman with severe emphysema at baseline LDCT in 2006. After 5.5 years (65.5 months) of follow-up, the participant died due to chronic obstructive pulmonary disease–related causes. Identifiable low-attenuation regions involved more than half of the lung parenchyma.
eMyosound to start cardiac ultrasound trial in 3 Boston hospitals
By AuntMinnie.com staff writers
The trial will validate eMyosound technology for the quantitative assessment of myocardial stiffness in patients with heart failure.
September 8, 2025
Heart Ultrasound Adobe Peakstock
ISCT: Mayo Clinic expert outlines how best to allocate PCCT resources
By Liz Carey
A Mayo Clinic radiologist discusses overcoming photon-counting CT (PCCT) operational challenges.
September 5, 2025
2025 09 05 Isct Temporal Bone Ossicular Impact Pcct Imaging Thumbnail
Follow-up analysis shows ELCAP's continued efficacy for CVD prediction
By Kate Madden Yee
Follow-up analysis of the ELCAP-CAC scoring system has shown it to be effective for predicting death from cardiovascular disease (CVD).
September 2, 2025
Chest Heart Pain
GE HealthCare unveils AI-loaded cardiovascular ultrasound system
By AuntMinnie.com staff writers
Adaptive cardiovascular ultrasound system redesigned for 2D, 4D, and color flow imaging.
August 29, 2025
Ge Healthcare Logo 8uqm Sjnztb
Echo images show consequences of steroid use among athletes
By Amerigo Allegretto
Echocardiography shows how anabolic steroid use among athletes impacts heart health.
August 29, 2025
Athlete Runner Chest Pain
DESKi launches cardiac AI software
By AuntMinnie.com staff writers
The software has been integrated into Butterfly Network’s handheld ultrasound devices.
August 27, 2025
Echocardiography
Philips cardiology snapshot highlights challenges for patient care, trust in AI
By AuntMinnie.com staff writers
Royal Philips shared findings from its Future Health Index cardiology snapshot that show challenges in cardiac care and AI.
August 26, 2025
Philips Rsna 2019 400
Esaote lands FDA clearance for two new MyLab ultrasound systems
By AuntMinnie.com staff writers
Esaote has received U.S. Food and Drug Administration (FDA) clearance to market its MyLab A50 and MyLab A70 ultrasound systems.
August 22, 2025
MyLab A70 ultrasound system.
POCUS performs well in assessing pathologic venous congestion
By Amerigo Allegretto
Point-of-care ultrasound (POCUS) showed success in venous excess ultrasound assessment of critically ill patients.
August 21, 2025
Ultrasound Diagnostic Control Panel 400
Page 1 of 328
Next Page